Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
FENC Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Fennec Pharmaceuticals Inc.NASDAQ: FENC
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $14.66M rose 59.3% year over year, ahead of the +31.8% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +25.0% a year.
Context
- Operating expenses amounted to 105.8% of revenue in FY2025, up 17.7 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +59.3% holds above the trailing-twelve-month pace of +31.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 47.22M USD
- Year-over-year change
- +12.8%
- 4-year CAGR
- +28.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.22M | +12.8% |
| FY2024 | 2024-12-31 | 41.88M | +26.7% |
| FY2023 | 2023-12-31 | 33.05M | +36.6% |
| FY2022 | 2022-12-31 | 24.19M | +40.4% |
| FY2021 | 2021-12-31 | 17.22M | — |
Operating Expenses vs competitors
How FENC compares with its peers on the latest reported figures
- FENC's LTM Mar 2026 operating expenses of $52.67M is the 10th highest of the 11 companies compared; the peer median is $77.51M.
- Its year-over-year change of +31.8% is the 4th highest of 11, against a peer median of +7.5%.
- Operating expenses amounts to 103.3% of revenue for FENC, versus a peer median of 929.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $140.97M | +26.8% | +7.2% | 1258.3% | |
| LTM Mar 2026 | $128.39M | -22.9% | -11.4% | 185.5% | |
| LTM Mar 2026 | $100.47M | -31.6% | -2.4% | 600.9% | |
| LTM Mar 2026 | $87.45M | +22.4% | +33.4% | 267.2% | |
| LTM Mar 2026 | $80.29M | -7.3% | -1.7% | 4523.5% | |
| LTM Mar 2026 | $74.72M | +140.4% | +76.7% | — | |
| LTM Mar 2026 | $68.54M | +51.5% | +11.9% | 116167.8% | |
| LTM Mar 2026 | $61.05M | -11.7% | +0.1% | — | |
| LTM Mar 2026 | $53.18M | -28.1% | -18.7% | — | |
| LTM Mar 2026 | $52.67M | +31.8% | +25.0% | 103.3% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $45.01M | +64.1% | +44.7% | — |
| Peer median (excluding FENC) | $77.51M | +7.5% | +3.7% | 929.6% | |
Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1.54M | 21.25M | 47.54M | 44.64M |
| Cost of Revenue | 0 | 86K | 1.26M | 3.18M | 3.76M |
| Gross Profit | 0 | 1.45M | 19.99M | 44.35M | 40.88M |
| Gross Margin | — | 94.4% | 94.1% | 93.3% | 91.6% |
| Research & Development | 4.98M | 3.53M | 56K | 307K | 250K |
| Selling, General & Admin | 12.24M | 20.51M | 32.71M | 41.48M | 46.91M |
| Operating Expenses | 17.22M | 24.19M | 33.05M | 41.88M | 47.22M |
| Depreciation & Amortization | 16K | 149K | 287K | 800K | 103K |
| EBITDA | (17.22M) | (22.59M) | (12.36M) | 4.8M | (7.45M) |
| EBITDA Margin | — | -1471.5% | -58.2% | 10.1% | -16.7% |
| Operating Income | (17.22M) | (22.74M) | (13.06M) | 2.48M | (6.35M) |
| Operating Margin | — | -1481.3% | -61.4% | 5.2% | -14.2% |
| Interest Income | 54K | 195K | 441K | 1.59M | 787K |
| Interest Expense | 126K | 978K | 3.39M | 4.07M | 2.08M |
| Other Income / Expenses | (123K) | (976K) | (2.99M) | (2.55M) | (3.29M) |
| Income Before Tax | (17.35M) | (23.71M) | (16.05M) | (71K) | (9.64M) |
| Pre-Tax Margin | — | -1544.9% | -75.5% | -0.1% | -21.6% |
| Income Tax Expense | 0 | 0 | 0 | 365K | 106K |
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Net Margin | — | -1544.9% | -75.5% | -0.9% | -21.8% |
| EPS (Basic) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| EPS (Diluted) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| Weighted Avg Shares | 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
| Weighted Avg Shares (Diluted) | 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
Intrinsic Alpha fair value
Locked
Current Price
$13.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.